Get started
Work

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy

Year: 2019
Type: article
Source: Oncogene
DOI: 10.1038/s41388-019-0732-7
Authors: Varadha Balaji Venkadakrishnan, Adam D. DePriest, Sangeeta Kumari, Dhirodatta Senapati, Salma Ben-Salem, Yixue Su, Giridhar Mudduluru, Qiang Hu, Eduardo Cortes, Elena Pop, James L. Mohler, Gissou Azabdaftari, Kristopher Attwood, Rajal B. Shah, Christina Jamieson, Scott M. Dehm, Cristina Magi-Galluzzi, Eric Klein, Nima Sharifi, Song Liu, Hannelore V. Heemers
Institutions: Cleveland State University, Cleveland Clinic, Roswell Park Comprehensive Cancer Center, University of California San Diego, University of Minnesota, Masonic Cancer Center
Language: English
Field: Medicine
Open Access status: green
Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, Roswell Park Cancer Institute, National Institutes of Health, National Cancer Institute, DOD Prostate Cancer Research Program
Awards: G1308892644, PKN1 AS NOVEL THERAPEUTIC TARGET IN ADVANCED PROSTATE CANCER, AR Gene Rearrangements and AR Signaling in Prostate Cancer, G2086761707, G215985982, G2515009731, G2860013413, G5640991198, Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF, G599720831, G6210030960, G6369261575, Prostate Cancer: Transition to Androgen - Independence (CA77739), G8445889297, Roswell Park Cancer Center Support Grant
OpenAlex ID: W2913471332
FWCI: 1.811
Cites: 63
Cited by: 21
Related to: 10